I-Afatinib Dimaleate CAS 850140-73-7 Purity >99.5% (HPLC) API
I-Ruifu Chemical Supply Intermediates ye-Afatinib
I-Afatinib CAS 439081-18-2
I-Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(I-Dimethylamino)i-acetaldehyde I-Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7
I-Diethylphosphonoacetic Acid CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-one CAS 162012-69-3
I-7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineI-CAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineI-CAS 314771-88-5
Igama Lekhemikhali | Afatinib Dimaleate |
Omqondofana | BIBW2992 Dimaleate;(S,E)-N-(4-(3-Chloro-4-Fluorophenylamino)-7-(Tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)kodwa-2-Enamide Dimaleate |
Inombolo ye-CAS | 618-89-3 |
Inombolo yeCAT | I-RF-PI2032 |
Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani |
I-Molecular Formula | I-C32H33ClFN5O11 |
Isisindo samangqamuzana | 718.08 |
Ukuzwela | Kuyazwela Umswakama |
Ibhrendi | I-Ruifu Chemical |
Into | Imininingwane |
Ukubukeka | Impushana Emhlophe Kuya Kumhlophe |
Ukuhlanzeka / Indlela Yokuhlaziya | >99.5% (HPLC) |
Ukulahlekelwa Ekumisweni | <0.50% |
Izinsalela ekushiseni | <0.10% |
Ukungcola Okukodwa Okukhulu | <0.30% |
Ukungcola Okuphelele | <0.50% |
Izinsimbi Ezisindayo (njenge-Pb) | ≤20ppm |
I-Infrared Spectrum | Ivumelana Nesakhiwo |
I-NMR | Ivumelana Nesakhiwo |
Izinga Lokuhlola | I-Enterprise Standard |
I-Shelf Life | Izinyanga Ezingu-24 Uma Zigcinwe Ngokufanelekile |
Ukusetshenziswa | I-API |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama
I-Afatinib Dimaleate (CAS: 850140-73-7), uhlobo lukasawoti oluyi-dimaleate lwe-afanitib, i-ejenti ye-antineoplastic etholakala ngomlomo.I-Afatinib Dimaleate iyi-EGFR inhibitor engabuyiseleki emuva enama-IC50s ka-0.5 nM, 0.4 nM, 10 nM kanye no-14 nM we-EGFRwt, EGFRL858R, EGFRL858R/T790M kanye ne-HER2, ngokulandelana.I-Afatinib Dimaleate ikhonjiswe ukwelashwa komugqa wokuqala weziguli ezinomdlavuza we-metastatic non-small cell lung cancer (NSCLC) amathumba azo anokususwa kwe-epidermal growth factor receptor (EGFR) exon 19 noma ukuguqulwa kwe-exon 21 (L858R) njengoba kutholwe yi-FDA- ukuhlolwa okugunyaziwe.Esikhathini esedlule, ukwelashwa okujwayelekile ngohlelo lwe-chemotherapy olusekelwe ku-platinum bekubhekwa njengokwelashwa okujwayelekile komugqa wokuqala kuzo zonke iziguli ezine-NSCLC.Kodwa-ke, ubufakazi obuvelayo buye bakhomba abantu abambalwa lapho ukwelashwa okuhlosiwe kusebenza kakhulu, okuholela ekwakhiweni kwezidakamizwa eziqondene nokuguquguquka.I-Afatinib Dimaleate Yasungulwa yi-Boehringer Ingelheim Pharmaceuticals, i-Afatinib Dimaleate yagunyazwa yi-FDA ngo-2013 njengesidakamizwa esiyintandane ngaphansi kwegama lokuhweba elithi Gilotrif.I-Afatinib Dimaleate ihlanganiswa ngamakhemikhali kusetshenziswa izindlela ezijwayelekile.Afatinib Dimaleateayisebenzi kuphela ngokumelene nokuguqulwa kwe-EGFR okuqondiswe i-TKI yesizukulwane sokuqala njenge-erlotinib noma i-gefitinib, kodwa futhi ngokumelene nokuguqulwa okufana ne-T790M engazweli kulezi zindlela zokwelapha ezijwayelekile.Ngenxa yomsebenzi wayo owengeziwe ngokumelene ne-Her2, kuphenywa umdlavuza webele kanye neminye imidlavuza eqhutshwa yi-EGFR kanye ne-Her2.